- Overview
- Financial Highlights
- Financial Report
- Announcement & Circular
- Investor Presentation
- Press Release
- Investor Event
- Analysts Coverage
- Prospectus
- Stock Information
- Policy and Contact
Overview
Financial Highlights
Results
For the ended 31 December
| (RMB’000) | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|
| Turnover | 864,621 | 754,115 | 739,132 | 2,758,152 | 2,667,978 |
| Gross Profit | 391,341 | 288,968 | 271,819 | 890,646 | 663,203 |
| Profit(loss) from operations | 96,071 | (577,638) | (1,117,190) | 365,552 | 255,537 |
| Profit (loss) before taxation | 17,327 | (652,841) | (1,177,288) | 307,469 | 210,158 |
| Profit (loss) for the year | 2,087 | (673,458) | (1,109,316) | 234,377 | 129,410 |
Assets and Liabilities
At 31 December
| (RMB’000) | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|
| Total non-current assets | 437,554 | 374,591 | 397,671 | 320,073 | 288,076 |
| Total current assets | 1,047,878 | 1,067,055 | 1,827,321 | 3,250,963 | 2,467,260 |
| Total current liabilities | 1,129,621 | 922,035 | 1,318,945 | 1,514,494 | 2,250,398 |
| Net current (liabilities) assets | (81,743) | 145,020 | 508,376 | 1,736,469 | 216,862 |
| Total assets less current liabilities | 355,811 | 519,611 | 906,047 | 2,056,542 | 504,938 |
| Total non-current liabilities | 142,832 | 310,812 | 21,053 | 1,235 | 2,661 |
| Net assets | 212,979 | 208,799 | 884,994 | 2,055,307 | 502,277 |
| Total equity attributable to equity shareholders of the Company | 212,979 | 208,799 | 884,994 | 2,040,177 | 487,147 |
Financial Report
YEAR
REPORT TYPE
Announcement & Circular
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
- 2011
Investor Presentation
- 2018
- 2016
- 2015
Press Release
- 2018
- 2016
- 2015
Investor Event
Prospectus
Prospectus
Stock Information
NT PHARMA （01011.HK）
（
%）
（Beijing time）
Shanghai Composite Index： ( %)
Shenzhen Component Index： ( %)
- Open
- Prev Close
- Highest
- Lowest
- Volume
- P/E Ratio
Policy and Contact
-
IR Policy and Contact
NT Pharma attaches great importance to corporate transparency and timely provides relevant information for shareholders. As a listed company (01011.HK) in main board of Hong Kong Exchanges and Clearing Limited, NT Pharma focuses on maintaining a high corporate transparency and governance level. It also tries to enable parties to know its business development strategy and growth potential better, by actively communicating with the investment market.
In this aspect, Corporate Financing and Investor Relations Department has established a series of systematic communication channels, so as to provide periodical and reliable information process for shareholders, investors and analysts. The webpage for investor relations of NT Pharma will be updated regularly, to show the updated information to the public and investors. Meanwhile, we also regularly organize timely exchange activities, including telephone conference, senior management’s meeting, a visit to any project, the participation in investment forums of securities companies, road show and seminar, to keep communication with investment community and market.
We believe that to maintain good and open relationships with media, analysts and investors is helpful to improve our market recognition and information transparency. Moreover, we avoid disclosing relevant information to some persons before making inside information public.
NT Pharma discloses information based on this principle, that is, it only interprets public information in the market to investors and basically discusses corporate business development. We avoid responding to any single or accumulative unpublished or possible inside information consultation by any individual. -
The comments of NT Pharma on Analysts Report are limited to:
(a) The published basic information
(b) Putting forward corrections on factual errors and assumptions according to the published information
According to the listing rules in Hong Kong, a quiet period is from 30 days before interim results of half a year and others to the publication date of such results, while the quiet period for publication of annual results is 60 days. Therefore, NT Pharma will not make any comment and forecast for financial performance at any interview or meeting during the quiet period.
-
Investor and media queries:
Corporate financing and investor relations
E-mail：ir@ntpharma.com
-
Hong Kong
Tel.：(852) 2808 1606
Fax：(852) 2508 9459
Address: Room 1505, 15/F, Bank of East Asia Harbour View Center, No. 56, Gloucester Road, Wanchai, Hong Kong